Navigation Links
Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
Date:9/10/2012

THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1.

Jordan will report directly to Robert A. Bradway, president and chief executive officer, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.

Since 2003 Jordan has served as communications leader at Johnson & Johnson, responsible for corporate communications and public affairs for more than 250 operating companies in 60 countries.  Prior to joining Johnson & Johnson, Jordan was vice president, communications and information, for Pfizer, where he held a range of positions over the course of 17 years. He also served as chair of PhRMA's public affairs section and of the National Pharmaceutical Council's User Group. Earlier in his career, Jordan was a reporter for a regional daily newspaper and held positions with Bristol-Myers and Dun & Bradstreet.

"We are very pleased to have Ray join Amgen," said Bradway.  "He is a strategic thinker and communicator with skills honed at two respected global health care companies.  Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid art
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... Md. , Sept. 2, 2014  Synthetic ... novel anti-infective biologic and drug candidates targeting specific ... today positive results from its final preclinical toxicology ... Administration (FDA) guidance, this bridging study was required ... candidate designed to prevent the devastating effects of ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
(Date:8/31/2014)... 2014 Available spectra is similar ... research and cultivation of a wide range of ... LEDs with proven patented and pending wide spectrum ... uniformity in critical applications in contrast to growth ... “Our customers have a large variety of differently ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... breed of pea seeds has been created that contains ... that attacks chickens. Researchers writing in the open access ... the GM seeds, and demonstrate their effectiveness in preventing ... a team of researchers from Novoplant GmbH, Germany, to ...
... , , HONG KONG, Sept. ... safe in patients who need coronary revascularization before undeferrable non-cardiac ... a paper published online in the International Journal of ... of print]). , , The paper, titled ...
... , LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies ... first in class collagenase-based products, today announced that BioSpecifics, President, ... the Biotech Industry" Conference on Wednesday, September 16, 2009, at ... Center in New York, NY. , , ...
Cached Biology Technology:OrbusNeich's Genous(TM) Bio-engineered R stent(TM) is Feasible in Patients Requiring Undeferrable Non-Cardiac Surgery, International Journal of Cardiology Publication Reports 2
(Date:9/2/2014)... study published in the September 2014 issue of ... Child and Adolescent Psychiatry found that children ... an increased risk of developing diabetes if they ... the nationwide Danish registers, a group of researchers ... University Hospital, Denmark, studied 48,299children and adolescents with ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
Breaking Biology News(10 mins):Risk of diabetes in children and adolescents exposed to antipsychotics 2Exceptionally well preserved insect fossils from the Rhône Valley 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3
... A spoonful of medicine goes down a lot easier if ... helpful for women living with HIV/AIDS and managing their chronic ... Bolton School of Nursing at Case Western Reserve University. ... managing other chronic illnesses," said Allison R. Webel, instructor of ...
... Ill. Land and marine iguanas and giant tortoises ... the Galpagos islands are more likely to harbor antibiotic-resistant ... sites on the islands, researchers report in a ... sites from free-living reptiles harbored Escherichia coli ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
Cached Biology News:CWRU study finds the love of a dog or cat helps women cope with HIV/AIDS 2Patterns of antibiotic-resistant bacteria found in Galapagos reptiles 2Moral imagination as a key to overcoming work-related stigmas 2
ssDNA from PCR DNA in less than 1 hour. No gels, columns, or slurries. Sequence from high quality ssDNA: clearer reads, longer runs....
... Freezerworks Unlimited includes 2 clients and streamlines sample ... sharing of freezers by multiple groups without the ... Network Client/Server version for Macintosh ... with 256 colors; OS 8.6 & OS 9.x ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
... Amplification Kit, 500 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
Biology Products: